Evidence map›Paper›PMID 40192823›Full record

Observational studyIntensive care medicine2025

Shortening antibiotic therapy duration for hospital-acquired bloodstream infections in critically ill patients: a causal inference model from the international EUROBACT-2 database.

Lena Gajdos, Niccolo Buetti, Alexis Tabah, Stephane Ruckly, Murat Akova, Frederik Sjöval, Kostoula Arvaniti, Jan de Waele, Hendrik Bracht, Francois Barbier and 2 more

Erratum issued Registry-linked trialAbstract readMulticenter StudyObservational Study
PubMed Publisher
In one paragraph

Observational study in Intensive care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03937245 (Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03937245 completednot on this map

Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care: the Eurobact II Multinational Cohort Study

Typeobservational_patient_registrySponsorOutcome ReaRan2019 to 2021Enrolled3,058ConditionsBacteremia, Sepsis, Hospital Acquired Condition, Resistance Bacterial
3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Lena GajdosOUTCOMEREA Research Group, Drancy, France.
Niccolo BuettiINSERM, IAME, U1137, Team DeSCID, Paris, France.
Alexis TabahQueensland University of Technology (QUT), Brisbane, Australia.
Stephane RucklyOUTCOMEREA Research Group, Drancy, France.
Murat AkovaDepartment of Infectious Diseases, Hacettepe University School of Medicine, Ankara, Turkey.
Frederik SjövalDepartment of Intensive and Perioperative Care, Skane University Hospital, Malmö, Sweden.
Kostoula ArvanitiIntensive Care Unit, Papageorgiou University Affiliated Hospital, Thessaloníki, Greece.
Jan de WaeleDepartment of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium.
Hendrik BrachtDepartment of Anesthesiology, Intensive Care, Emergency Medicine, Transfusion Medicine, and Pain Therapy, University Hospital of Bielefeld, Campus Bielefeld-Bethel, Bielefeld, Germany.
Francois BarbierCentre Hospitalier Régional d'Orléans, Tours, France.
Jean-François TimsitOUTCOMEREA Research Group, Drancy, France. Jean-francois.timsit@aphp.fr.ORCID 0000-0002-6063-7383
EUROBACT-2 Study Group, the European Society of Intensive Care Medicine (ESICM), the European Society of Clinical Microbiology, the Infectious Diseases (ESCMID) Study Group for Infections in Critically Ill Patients (ESGCIP) and the OUTCOMEREA Network

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionHospital-acquired bloodstream infections (HA-BSIs) are severe and require antibiotic therapy. In non-complicated BSIs, shortened therapy reduces side effects without compromising efficacy. The impact of shortened antibiotic therapy in HA-BSI critically ill patients without indication of prolonged therapy requires further evaluation.

methodsUsing the international prospective EUROBACT-2 cohort, we compared shortened (7-10 days) versus long (14-21 days) treatment durations in ICU patients eligible for shortened therapy. Patients without antibiotic therapy within 3 days after HA-BSI occurrence or requiring prolonged therapy (due to infection source, microorganism, or clinical deterioration) were excluded. Treatment failure, defined as death, persistent infection, or subsequent infectious complications by Day 28, was assessed using an inverse-probability of treatment weighted (IPTW) logistic regression.

resultsAmong 2600 patients, 550 were eligible for shortened treatment, 213 received short, and 337 received long treatment. The most common infection source was intravascular catheters (33%), most common microorganisms were Enterobacterales (39%). Patients with long treatment were more frequently infected with Staphylococcus aureus (11% vs. 5.6%, p = 0.025) or difficult-to-treat microorganisms (23% vs. 7%, p < 0.001), and received more commonly combination therapy (46% vs. 30%, p < 0.001). Short treatment was associated with reduced 28-day treatment failure (OR 0.64, 95% CI 0.44-0.93, p = 0.019), mainly due to reduction in subsequent infectious complications (OR 0.58, 95% CI 0.37-0.91, p = 0.018). Mortality (OR 0.92 [95% CI 0.59, 1.43], p = 0.7) and persistent infection rates (OR 0.47 [95% CI 0.17, 1.14], p = 0.12) were similar.

conclusionsIn selected ICU patients with HA-BSI, shortened antibiotic treatment might be considered. Eurobact2 was a prospective international cohort study, registered in ClinicalTrials.org (NCT03937245).

Indexed as

Anti-Bacterial AgentsBacteremiaCross InfectionDuration of TherapyAgedCritical IllnessDatabases, FactualFemaleHumansIntensive Care UnitsMaleMiddle AgedProspective StudiesTime FactorsAnti-Bacterial AgentsAntibiotic therapy durationCritically illHospital-acquired bloodstream infection

Identifiers

PMID40192823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.